On March 10, 2021 GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage biopharmaceutical company focused on the development and commercialization of disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology, TriKE, for the treatment of cancer and infectious diseases, reported that management will present at the Virtual 33rd Annual Roth Conference on Wednesday, March 17th, 2021 at 12:00 p.m. ET (9:00am PT) (Press release, GT Biopharma, MAR 10, 2021, View Source [SID1234576378]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation may be accessed by visiting the Investors section of the GT Biopharma website at View Source An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.

About GTB-3550 TriKE

GTB-3550 TriKE is a first-in-class immuno-oncology therapeutic being evaluated in patients age 18 and older in a Phase I/II clinical trial (NCT03214666) having CD33+ malignancies (primary induction failure or relapsed AML with failure of one reinduction attempt or high-risk MDS progressed on two lines of therapy). Interim results demonstrated GTB-3550 TriKE reduces bone marrow blast levels in AML and MDS patients, and improved NK cell function and proliferation.